Direct and Indirect Effects of Pneumococcal Protein Conjugate Vaccine

Eunhwa Choi

doi:10.5124/jkma.2008.51.2.119

J Korean Med Assoc > Volume 51(2); 2008 > Article

Choi: Direct and Indirect Effects of Pneumococcal Protein Conjugate Vaccine

Focused Issue of This Month

Newly Developed Vaccines and New Vaccination

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2008; 51(2): 119-126.

Published online: February 28, 2008

DOI: http://dx.doi.org/10.5124/jkma.2008.51.2.119

Direct and Indirect Effects of Pneumococcal Protein Conjugate Vaccine

Eunhwa Choi, MD

Department of Pediatrics, Seoul National University College of Medicine, Korea. eunchoi@snu.ac.kr

Abstract

Streptococcus pneumoniae is a major etiology of serious bacterial infection among children worldwide. Among the 91 serotypes, the majority of invasive infections are caused by 10 common serotypes, 14, 16, 18, 19, 23, 4, 9, 7, 1, and 3. However, the ranking and serotype prevalence differ by age group and country. The heptavalent pneumococcal conjugate vaccine (PCV7) was licensed for use among infants and young children in many countries including Korea. The routine use of PCV7 has resulted in a decreased incidence of invasive pneumococcal disease by the vaccine serotypes among the vaccines (direct effect). However, it is notable that substantial declines in invasive diseases among older children and adults ensued through indirect effects on transmission (i.e., herd immunity). In addition, there are increasing evidences to suggest that routine immunization with PCV7 is changing the epidemiology of pneumococcal diseases such as serotype distribution of invasive disease, nasopharyngeal colonization, and antibiotic resistance patterns. In contrast, there is a small increase in the number of invasive diseases caused by nonvaccine serotypes, so called 'replacement phenomenon', though it is still minor compared with overall declines of vaccine-serotype diseases. Of those, the increase in the 19A-related disease has become most prominent. In Korea, a remarkable increase of 19A was noted before the introduction of PCV7. The emergence of resistance and replacement of disease by nonvaccine strains should be closely monitored.

S. pneumoniae; Pneumococcal conjugate vaccine; Serotype; Effectiveness

References

1. Dagan R, Jacobs MR, Greenberg D. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan S, editor. Pneumococcal infections. Textbook of Pediatric Infectious DIseases 2004;Vol 1:5th ed. Philadelphia: WB Saunders. 1204-1258.

2. O'Brien KL, Santosham M. Potential impact of conjugate pneumococcal vaccines on pediatric pneumococcal diseases. Am J Epidemiol 2004;159:634-644.

3. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(RR-9):1-55.

4. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000;106:362-366.

5. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR 2005;54:893-897.

6. Black S, Shinfield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-195.

7. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, Kumar G, Parkinson A, Hu D, Hackell J, Change I, Kohberger R, Siber G, Santosham M. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 2003;362:355-361.

8. Whitney CG, Farley MM, Hadler J, Harrison LH. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-1746.

9. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of pneumococcal conjugate vaccine coverage. JAMA 2007;297:1784-1792.

10. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368:1495-1502.

11. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005;365:1139-1146.

12. Schutze GE, Tucker NC, Mason EO Jr. Impact of the conjugate pneumococcal vaccine in arkansas. Pediatr Infect Dis J 2004;23:1125-1129.

13. Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, Korgenski K, Firth S, Glover D, Jensen J, Mason EO, Shutt CK, Pavia AT. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005;41:21-29.

14. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006;25:250-254.

15. Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004;10:811-813.

16. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, Siber G, Makela PH. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-409.

17. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005;116:408-413.

18. Whitney CG. Impact of conjugate pneumococcal vaccines. Pediatr Infect Dis J 2005;24:729-730.

19. Moore MR, Hyde TB, Hennessy TW, Parks DJ, Reasonover AL, Harker-Jones M, Gove J, Bruden DL, Rudolph K, Parkinson A, Butler JC, Schuchat A. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J Infect Dis 2004;190:2031-2038.

20. Millar EV, O'Brien KL, Watt JP, Bronsdon MA, Dallas J, Whitney CG, Reid R, Santosham M. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 2006;43:8-15.

21. Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 2004;23:1015-1022.

22. Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003;22:532-540.

23. Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Yogev R, Barson WJ. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004;113:443-449.

24. Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004;23:485-489.

25. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, Schaffner W, Craig AS, Edwards KM, Griffin MR. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004;39:641-648.

26. Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, Orenstein WA, Arnold K, Schuchat A, Farley MM. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005;365:855-863.

27. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-1463.

28. Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D, Pelton SI, Goldstein R, Huot H, Finkelstein JA. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007;195:347-352.

29. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007;44:1569-1576.

30. Gertz RE Jr, McEllistrem MC, Boxrud DJ, Li Z, Sakota V, Thompson TA, Facklam RR, Besser JM, Harrison LH, Whitney CG, Beall B. Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 2003;41:4194-4216.

31. Beall B, McEllistrem MC, Gertz RE, Wedel S, Boxrud DJ, Gonzalez AL, Medina MJ, Pai R, Thompson TA, Harrison LH, McGee L, Whitney CG. Pre-and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006;44:999-1017.

32. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005;192:1988-1995.

33. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, Huang SS, Goldstein R, Hanage WP. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007;26:468-472.

34. Messina AF, Katz-Gaynor K, Barton T, Ahmad N, Ghaffar F, Rasko D, McCracken GH Jr. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 2007;26:461-467.

35. Kim SH, Song EK, Lee JH, Kim NH, Lee JA, Choi EH, Lee HJ. Changes of serotype distribution of Streptococcus pneumoniae isolated from children in Korea over a 15 year-period (1991~2005). Korean Journal of Pediatric Infectious Diseases 2006;13:89-98.

36. Kim NH, Lee J, Lee SJ, Lee H, Kim KH, Park SE, Lee HJ. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein conjugate; Prevenar) in Korean infants: differences that are found in Asian children. Vaccine 2007;25:7858-7865.

37. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editor. American Academy of Pediatrics. Influenza. Red Book: 2006 Report of the Committee on Infectious Diseases 2006;27th ed. Elk Grove Village IL: American Academy of Pediatrics. 525-537.

38. Lee HJ, Choi EH, Kim MJ, Cheon BC. Change of etiologic agents in invasive infections among immunocompetent child-ren from the multicentered study and distribution of serotype of Streptococcus pneumoniae during the period, 2003~2006 2006;Korea Center for Disease Control and Prevention.

Figure 1

Rate^* of vaccine-type (VT) invasive pneumococcal diseases (IPD) before and after introduction of pneumococcal conjugate vaccine (PCV7), by age group and year-Active Bacterial Core Surveillance, United States, 1998~2003 (5)

^*Per 100,000 population.

^†For each age group, the decrease in VT IPD rate for 2003 compared with the 1998~1999 baseline is statistically significant (P<0.05).

Table 1

Recommended schedule for doses of 7-valent pneumococcal conjugate vaccine (PCV7), including catch-up immunizations in previously unimmunized and partially immunized children

^*For children immunized at < 12 mo, the minimum interval is 4 weeks. Doses administered at ≥ 12 mo should be ≥ 8 weeks apart.

^†Children with asplenia, chronic heart or lung disease, diabetes mellitus, cerebrospinal fluid leak, coch lear implant, sickle cell disease, HIV infection, or another immunocompromising condition.